Back to Trials
Accepting PatientsObservationalNCT05281445

Exploring the Role of Neuroactive Steroids in Tourette Syndrome

Tourette Syndrome in Children

Phase:Observational
Status:Accepting Patients
Age:8 - 12
Gender:All
Locations:1 site

What This Study Is About

Tourette syndrome (TS) is a disabling neurodevelopmental disorder characterized by motor and phonic tics. The studies proposed in this application will explore the endocrine mechanisms underlying two of the least well-understood biological characteristics of TS, namely its marked male predominance and stress susceptibility. In particular, our exploratory studies will characterize the steroid profile in TS-affected boys and girls to identify novel potential biomarkers and therapeutic targets for this disorder.

Who Can Participate

You May Qualify If
  • Diagnostic criteria of TS for cases (and lack of any tic disorders for controls)
  • Age between 8 and 12 years old (this age range is to ensure that TS participants can perform the tic suppression task)
  • confirmation of sexual development by parent and/or self-reported Tanner stage of pubic hair development.
You Cannot Join If
  • major psychiatric disorders such as a psychotic disorder, autism spectrum disorder, conduct disorder, and substance use disorder;
  • other neurological disorders;
  • clinically significant endocrinological disorders;
  • use of therapies that can modify hormonal profile;
  • pharmacotherapies that may change stress sensitivity, such as antidepressants and anxiolytics.
View Full Eligibility Criteria
Full Criteria (from ClinicalTrials.gov)

Inclusion Criteria: * Diagnostic criteria of TS for cases (and lack of any tic disorders for controls) * Age between 8 and 12 years old (this age range is to ensure that TS participants can perform the tic suppression task) * confirmation of sexual development by parent and/or self-reported Tanner stage of pubic hair development. Exclusion Criteria: * major psychiatric disorders such as a psychotic disorder, autism spectrum disorder, conduct disorder, and substance use disorder; * other neurological disorders; * clinically significant endocrinological disorders; * use of therapies that can modify hormonal profile; * pharmacotherapies that may change stress sensitivity, such as antidepressants and anxiolytics.

Important: This is a summary. The final determination of eligibility will be made by the trial coordinator after reviewing your complete medical history.

Study Locations

University of Utah — Salt Lake City, Utah

Contact

Contact

Marco Bortolato, MD PhD

Experimental Treatment

This trial is testing a new treatment. Results are not guaranteed. Talk to your doctor before applying.

Apply to This Trial

Your information will be sent to the study coordinator for review.